News AZ highlights data from next-gen oncology drugs at ASCO Tesara and Takeda among other companies to publish data.
News Tesaro's niraparib approved in ovarian cancer Company nabs maintenance therapy use, but problems on breast cancer trial.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
